Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19:153-158

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Serebruany, V. L.
Right arrow Articles by Gurbel, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Serebruany, V. L.
Right arrow Articles by Gurbel, P. A.
Related Collections
Right arrow Cardiovascular Pharmacology
Right arrow Anticoagulant mechanisms
Right arrow Acute myocardial infarction
Right arrow Platelets
Right arrow Endothelium/vascular type/nitric oxide
(Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19:153-158.)
© 1999 American Heart Association, Inc.


Original Contributions

Effect of Thrombolytic Therapy on Platelet Expression and Plasma Concentration of PECAM-1 (CD31) in Patients With Acute Myocardial Infarction

Victor L. Serebruany; Paul A. Gurbel

From the Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, Md.

Correspondence to Victor L. Serebruany, MD, PhD, Center for Thrombosis Research, Sinai Hospital of Baltimore, 2401 W Belvedere Ave, Schapiro Research Building R202, Baltimore, MD 21215. E-mail Heartdrug{at}aol.com


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Abstract—Animal studies have shown that the administration of antibodies against platelet/endothelial cell adhesion molecule-1 (PECAM-1) before reperfusion can reduce infarct size. The purpose of the present study was to define the effects of thrombolytic therapy in acute myocardial infarction (AMI) patients on the platelet expression and plasma concentrations of PECAM-1 at prespecified time points after attempted reperfusion. The plasma concentration and platelet expression of PECAM-1 were determined in 23 AMI patients enrolled in the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO-III) trial before thrombolysis and at 3, 6, 12, and 24 hours thereafter and compared with 22 healthy controls. At baseline, PECAM-1 was expressed significantly more on the platelet surface in the AMI patients than in controls (P=0.027) while soluble PECAM-1 plasma levels were almost identical between groups. There were no significant diurnal variations in both plasma and platelet PECAM-1 levels in controls. A significant decrease in platelet PECAM-1 expression was observed 3 hours after thrombolysis (P=0.03) compared with baseline, followed by a significant increase (P=0.004) in fluorescence intensity later at 24 hours after thrombolysis. Conversely, a significant increase in soluble PECAM-1 was observed 3 hours after thrombolysis (P=0.02), followed by a significant decrease later at 24 hours after attempted reperfusion (P=0.03). The expression of platelet-bound PECAM-1 is increased in AMI patients. Discordantly directed changes in soluble and platelet PECAM-1 after the first 24 hours after thrombolytic therapy may represent redistribution of the whole PECAM-1 pool. Further investigation of the possible role of PECAM-1 and the relationship between its soluble and platelet fractions in AMI are warranted.


Key Words: PECAM-1 • acute myocardial infarction • thrombolysis • humans


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Platelet/endothelial cell adhesion molecule-1 (PECAM-1, CD31), a 130-kDa integral membrane glycoprotein (GP) and a member of the immunoglobulin gene superfamily, is found on the surface of platelets and leukocytes and at intercellular junctions of endothelial cells.1 2 PECAM-1 is directly involved in the formation of the vascular bed, affects the upregulation of integrin function on leukocytes, and has been implicated as a trigger that regulates leukocyte trafficking through the vessel wall.3 4 5 As an {alpha}-granule constituent, PECAM-1 is a distinct, well-defined component of the platelet plasma membrane, with an intracellular distribution identical to that of GP IIb/IIIa.6 Native, resting human platelets express {approx}8000 molecules per platelet, whereas thrombin-stimulated platelets exhibit nearly 2-fold expression.7

A soluble form of PECAM-1, which is 5 to 10 kDa smaller than platelet-associated PECAM-1, contains a cytoplasmic tail and is encoded by an alternatively spliced mRNA from which the exon containing the transmembrane domain has been removed.8 Despite the proposed importance of PECAM-1, little is known about its biosynthesis, processing, and turnover on the cell surface.

Limited evidence from in vitro9 and animal10 studies show that monoclonal antibodies against PECAM-1 block leukocyte migration and neutrophil accumulation and reduce acute inflammation. Recognizing the role of leukocytes in the pathogenesis of acute coronary thrombosis and the modulation of injury after reperfusion, it is reasonable to expect that anti–PECAM-1 antibodies may diminish infarct size. Indeed, the administration of monoclonal antibodies against PECAM-1 resulted in a significant reduction in infarct size, presumably via blockade of neutrophil accumulation in the myocardium in both rats11 and cats.12 These studies suggest that PECAM-1 may be an attractive target for a novel, adjunctive therapeutic approach in the treatment of acute myocardial infarction (AMI).

However, the role of PECAM-1 in acute coronary syndromes has been suggested but never explored. No data are available on platelet PECAM-1 expression and plasma levels in AMI patients; similarly, the effects of thrombolytic therapy are unknown. Moreover, possible diurnal variations in platelet and plasma PECAM-1 levels in healthy controls have not been elucidated. Simultaneous determination of both platelet and soluble forms could lead to the discovery of helpful correlations between PECAM-1 and arterial patency, the success of thrombolysis, infarct size, reocclusion, or reinfarction.

Thus, the purpose of the present study was to define the immediate, early, and delayed effects of thrombolytic therapy in AMI patients enrolled in the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO-III) trial on the platelet expression and plasma concentrations of PECAM-1 at prespecified time points after attempted reperfusion and to compare these results with a cohort of healthy controls matched over the same time period at the same time of day.


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
This study was approved by the Institutional Review Boards of St Agnes Hospital and Union Memorial Hospital (Baltimore, Md). Informed, written consent was obtained from all participants of the study.

Controls
Ten nonsmoking, nondiabetic subjects (aged 21 to 43 years; 6 men, 4 women) without a history of bleeding disorders, hypertension, and cardiovascular disease and who did not use pharmacological agents for at least 2 weeks before the study were enrolled. All subjects underwent blood sampling after at least 30 minutes of rest and 2 or more hours of fasting. From 12 additional volunteers, blood was drawn 6 times every 4 hours over a 24-hour period to determine any possible diurnal influence and was sampled from an antecubital vein as in the experimental group.

Patients
Twenty-three consecutive patients admitted to the emergency departments of St Agnes Hospital or Union Memorial Hospital between July and December 1996 with a diagnosis of AMI were included. All patients were enrolled in the randomized trial of reteplase (n=13) versus accelerated alteplase (n=10) for treatment of AMI (GUSTO-III trial).13 The inclusion criteria have been previously reported.13 In summary, patients of any age who presented within 6 hours of symptom onset with >30 minutes of continuous symptoms of AMI and who, on a 12-lead ECG, had demonstrated at least a 1-mm ST-segment elevation in 2 or more limb leads, at least a 2-mm ST-segment elevation in 2 or more contiguous precordial leads, or bundle branch block were included in this trial. Patients were excluded if they had a history of bleeding diathesis, stroke, major surgery, or significant trauma in the previous 6 weeks and a blood pressure reading >200/110 mm Hg. Patients randomized to reteplase therapy received 2 intravenous 10-MU boluses given 30 minutes apart. Those randomized to alteplase received an accelerated dosing regimen: a 15-mg bolus, then 0.75 mg/kg over 30 minutes, and 0.50 mg/kg over 1 hour. During baseline sampling, every patient received 325 mg aspirin and at least 5000 U intravenous heparin. After administration of the thrombolytic therapy, all patients received a continuous infusion of heparin for the first 24 hours as recommended in the GUSTO-III protocol. Blood samples for ELISA and for flow-cytometric studies were taken at prespecified intervals: in the emergency department immediately before administration of the thrombolytic therapy; in the coronary care unit at 3, 6, and 12 hours; and finally at 24 hours thereafter. To avoid possible observer bias, blood samples were coded and blinded. Sampling procedures, ELISA, and flow-cytometric studies were performed by individuals unaware of the protocol.

Time Course and Exclusion of Blood Samples
The schedules for blood drawing, sample preparation, and processing were critical issues of the study design and were monitored by an independent observer. The actual timing of blood collection for the baseline sample was 9.5±1.4 minutes before the start of thrombolytic therapy, 174.6±21.8 minutes for the 3-hour sample, 371.1±24.2 minutes for the 6-hour sample, 709.4±17.8 minutes for the 12-hour sample, and 1402.9±18.8 minutes for the 24-hour sample. Samples were processed within 1 hour after blood drawing. Four patients did not complete the protocol at various time points. The reasons for early termination were patient transfer for emergency coronary angioplasty (3) and inability to obtain a blood sample (1). Twenty-three baseline samples, 22 samples collected at 3 hours, 20 samples collected at 6 hours, 20 samples collected at 12 hours, and 19 samples collected at 24 hours were included in the study analysis.

Soluble PECAM-1
Platelet-poor plasma was obtained by centrifugation of whole blood at 4°C in a Labofuge at 3000g for 10 minutes. Samples were stored at -80°C before final determinations. An ELISA for PECAM-1 (Bender MedSystems) was used according to standard techniques. Each sample was measured in triplicate, and the overall intra-assay coefficient of variation was 2.1±0.3%.

Platelet-Bound PECAM-1
Flow-cytometry procedures have been previously described in detail.14 15 In brief, venous blood (8 mL) was collected in a plastic tube containing 2 mL acid-citrate-dextrose (ACD) and mixed well. The blood-ACD mixture was centrifuged at 1000 rpm for 10 minutes at room temperature. The upper 2/3 of the platelet-rich plasma (PRP) was then collected and adjusted to pH 6.5 by adding ACD. The PRP was then centrifuged at 3000 rpm for 10 minutes. The supernatant was removed and the platelet pellet gently resuspended in 4 mL of the washing buffer (10 mmol/L Tris-HCl, 0.15 mol/L NaCl, and 20 mmol/L EDTA, pH 7.4). Platelets were washed 4 times in the washing buffer and an additional 4 times in Tris-buffered saline (10 mmol/L Tris and 0.15 mol/L NaCl, pH 7.4). One portion of washed platelets was incubated with 5 µL FITC-conjugated antibodies in the dark at 4°C for 30 minutes, and 1 part remained unstained and served as a negative control. Surface antigen expression was determined with monoclonal murine anti-human antibodies to CD31 (PECAM-1; PharMingen, San Diego, Calif). After incubation, the cells were washed 3 times with Tris-buffered saline and resuspended in 0.25 mL of 1% paraformaldehyde. Samples were stored at 4°C and analyzed on a Becton-Dickinson FACScan flow cytometer with a laser output of 15 mW, an excitation wavelength of 488 nm, and emission detection at 530±30 nm. The instrument was calibrated daily with fluorescence beads (CaliBRITE; Becton-Dickinson) and measured FITC-conjugated fluorescence intensity. All parameters were obtained by logarithmic amplification to the fourth decimal place. The data were collected and stored in list mode and then analyzed with CELLQuest (version 1.2.2) software.

Statistical Analyses
A post hoc t test comparison using the Bonferroni correction was performed to identify specific differences in soluble PECAM-1 and platelet receptor expression between AMI patients and controls and between different time points within the control and AMI groups. A Mann-Whitney U test was used to analyze nonparametric data. Normally distributed data are expressed as mean±SD, and P<0.05 was considered significant. Differences between individual flow-cytometric histograms were assessed using the Smirnov-Kolmogorov test incorporated in the CELLQuest software.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
The clinical characteristics of the AMI patients are shown in Table 1Down. Table 2Down and Figure 1Down summarize the data on the soluble and platelet-bound PECAM-1 levels in AMI patients before and after thrombolytic therapy and in healthy controls. Individual data on the diurnal variations in healthy volunteers are plotted for soluble (Figure 2ADown) and platelet-bound (Figure 2BDown) PECAM-1. There were no meaningful differences in diurnal variations in healthy volunteers. However, platelet-bound PECAM-1 was slightly higher during the night and early morning hours.


View this table:
[in this window]
[in a new window]
 
Table 1. Characteristics of the AMI Patients


View this table:
[in this window]
[in a new window]
 
Table 2. Soluble and Platelet-Bound PECAM-1 Levels in AMI Patients After Thrombolytic Therapy and in Healthy Controls



View larger version (12K):
[in this window]
[in a new window]
 
Figure 1. Dynamic changes of the soluble (circles) and platelet-bound (squares) PECAM-1 levels (mean±SD) during the first 24 hours after coronary thrombolysis. The highest plasma PECAM-1 level is associated with the lowest platelet expression at 3 hours, and oppositely, the lowest plasma level with the corresponding highest platelet expression at 24 hours.



View larger version (12K):
[in this window]
[in a new window]
 
Figure 2. Representative individual plots and means of plasma levels (A) and of platelet-bound PECAM-1 expression (B) in 12 healthy volunteers over 24 hours. Platelet P-selectin is slightly higher during the night and morning hours.

Plasma PECAM-1
At baseline, the data were almost identical between controls and the AMI group. A significant increase of plasma PECAM-1 was observed 3 hours after thrombolysis (P=0.02) and was followed by a significant decrease later at 24 hours (P=0.03).

Platelet-Bound PECAM-1
At baseline, before any reperfusion strategies were applied, PECAM-1 was expressed significantly more on the platelet surface of the AMI patients compared with controls (P=0.027). A significant decrease of platelet PECAM-1 expression was observed 3 hours after thrombolysis (P=0.03) when compared with baseline, followed by a significant increase (P=0.004) in fluorescence intensity later at 24 hours after thrombolysis.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
The data from the present study describe the time course of soluble and platelet-bound PECAM-1 levels after thrombolytic therapy in patients with AMI. A negative correlation was observed for soluble and platelet-bound PECAM-1 at 3 and 24 hours after thrombolysis. That is, while plasma PECAM-1 increased early after thrombolysis, platelet expression of PECAM-1 diminished at the same time point. Conversely, later after thrombolytic administration, soluble PECAM-1 levels dropped below baseline while platelet expression increased significantly (Figure 1Up). The present data suggest that plasma levels and platelet expression of PECAM-1 are inversely related to each other during the course of thrombolysis for AMI. Future basic studies are necessary to determine the normal distribution of the human PECAM-1 pool and the factors affecting this adhesion molecule.

This study also demonstrates that the expression and plasma levels of PECAM-1 in the AMI population are heterogeneous. We have observed similar heterogeneity with other platelet-surface receptors, including P-selectin and GP IIb/IIIa. Contrary to expectations, we did not observe marked PECAM-1 activation at baseline in the AMI population when compared with controls. Certain individuals exhibited a 2-fold increase in PECAM-1; however, more than a half of AMI patients have a platelet expression of PECAM-1 that is within the normal range or lower. Furthermore, the soluble PECAM-1 level was identical between the AMI group and healthy controls.

Platelets have established interactions with both physiological and drug-induced fibrinolysis.16 For example, platelet {alpha}-granules, in addition to containing PECAM-1, incorporate plasminogen activator inhibitor-116 and {alpha}2-antiplasmin.17 Release of these proteins theoretically could result in reduced thrombolysis. The resistance to arterial opening after thrombolysis has been reported in animal models of platelet-rich coronary thrombi.18 Studies supporting the "platelet hypothesis" have demonstrated enhanced reperfusion with concomitant use of antibodies and other antagonists to GP IIb/IIIa.19 20 In addition, it has recently been demonstrated that systemically administered antibodies against GP IIb/IIIa alone, presumably by facilitating platelet disaggregation, can restore infarcted artery reperfusion.21 Nevertheless, the relative contribution of each of the individual platelet-surface receptors to platelet-mediated vessel occlusion in the pathogenesis of AMI remains undefined.

Flow cytometry has been found to be a sensitive, objective, and reproducible method for the detection and measurement of platelet receptors.14 15 A large number of cellular antigens have been demonstrated on platelets by flow cytometry, and their quantification is an objective and accurate method.22 Some of the platelet receptors (eg, GP IIb/IIIa, P-selectin) are relatively well described, and their role in acute coronary syndromes is under thorough investigation, whereas much less is known about other surface GPs, including PECAM-1.

The involvement of PECAM-1 in platelet adhesion and aggregation remains a matter of considerable controversy. Anti–PECAM-1 monoclonal antibodies did not inhibit platelet aggregation or platelet adherence to the extracellular matrix7 and had no effect on platelet aggregate formation after epinephrine-induced activation23 in humans. However, although no effects of PECAM-1 on platelet aggregation have been reported, an important role in aggregation-induced cell signaling has been observed.24 In contrast, PECAM-1 has been implicated in platelet aggregation25 and has been described as an important modulator of platelet function in mice.26 Our data on the diminished platelet expression of PECAM-1 followed by its increase later during thrombolysis is in agreement with the few available observations on the dynamic patterns of the platelet-27 and neutrophil-28 expressed PECAM-1 during cardiopulmonary bypass in humans.

Another meaningful issue is an obvious concern for a possible diurnal variation of PECAM-1 in normal controls, which were described earlier for the fibrinolytic system29 and platelet serotonin transport30 but not for platelet aggregability31 and membrane {alpha}2-adrenoceptor expression32 or eicosanoid urinary excretion.33 Diurnal variations are important because there is clear clinical evidence of circadian patterns in myocardial ischemic episodes. In patients with effort angina, the highest activity occurs between 6 AM and noon. This maximum coincides with peaks in the diurnal variation in frequency of AMI, stroke, and sudden death.34 35 Indeed, we found no significant diurnal variations in both soluble and platelet PECAM-1 values; however, slightly higher levels of platelet-bound PECAM-1 expression during the night and early morning hours are in full agreement with the above-mentioned studies.

There are several limitations of the study. The sample size is small and therefore is compromised by low power. Statistical differences between and within groups in the soluble form and in surface platelet receptor expression could possibly be revealed in a larger sample of patients. It will be important in future studies to determine possible interactions between PECAM-1 and more-explored platelet antigens like GP IIb/IIIa and P-selectin and to develop specific anti–PECAM-1 strategies in patients with acute coronary syndromes. In addition to the observed differences in PECAM-1, clinical characteristics such as use of antecedent aspirin and the timing of thrombolytic agent delivery may influence the results.

In conclusion, PECAM-1 plasma concentrations are dynamic after thrombolytic therapy in AMI patients and exhibit an early rise followed by a slow decline. The mechanism of the above observation is unknown but may be related to myocardial reperfusion. An enticing speculation is that it is derived from the ischemic vascular bed after reperfusion. Platelet PECAM-1 is increased at baseline in the AMI population, declines early after reperfusion, and is followed by a second phase of enhanced expression. This phenomenon, observed with other platelet antigens, may indicate delayed platelet activation after thrombolysis.

The determination of the role of less-studied platelet and endothelial receptors in patients with AMI cannot be overstated. Given the predominance of PECAM-1 on the endothelium, its proposed importance in transendothelial migration of leukocytes, and the role of leukocytes and platelets in coronary thrombosis, further investigation of the relation between soluble and platelet PECAM-1 fractions in myocardial ischemia/reperfusion is warranted.


*    Acknowledgments
 
This study was supported in part by Medtronic, Inc, and Boehringer Mannheim GmbH (to V.L.S. and P.A.G.). We are indebted to the staff of the emergency departments and critical care units of St Agnes and Union Memorial Hospitals.

Received November 4, 1997; accepted June 30, 1998.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 
1. Newman PJ, Berndt MC, Gorsky J, White GC, Paddock LS, Muller WA. PECAM-1 (CD 31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. Science. 1990;247:1219–1223.[Abstract/Free Full Text]

2. Muller WA, Berman ME, Newman PJ, DeLisser HM, Albelda SM. A heterophylic adhesion mechanisms for platelet/endothelial adhesion molecule 1 (CD 31). J Exp Med. 1992;175:1401–1404.[Abstract/Free Full Text]

3. Vaporciyan AA, DeLisser HM, Yan HC, Mendiguren II, Thom SR, Jones ML, Ward PA, Albelda SM. Involvement of platelet-endothelial cell adhesion molecule-1 in neutrophil recruitment in vivo. Science. 1993;262:1580–1582.[Abstract/Free Full Text]

4. Muller WA, Weigl SA, Deng H, Phillips DM. PECAM-1 is required for transendothelial migration of leukocytes. J Exp Med. 1993;178:449–460.[Abstract/Free Full Text]

5. Carlos TM, Harlan JM. Leukocyte-endothelial cell adhesion molecules. Blood. 1994;84:2069–2101.

6. Cramer EM, Berger G, Berndt MC. Platelet {alpha}-granule and plasma membrane share two new components: CD9 and PECAM-1. Blood. 1994;84:1722–1730.[Abstract/Free Full Text]

7. Metzelaar MJ, Korteweg J, Sixma JJ, Nieuwenhuis HK. Biochemical characterization of PECAM-1 (CD 31 antigen) on human platelets. Thromb Haemost. 1991;66:700–707.[Medline] [Order article via Infotrieve]

8. Golderger A, Middleton KA, Oliver JA, Paddock C, Yan HC, DeLisser HM, Albelda SM, Newman PJ. Biosynthesis and processing of the cell adhesion molecule PECAM-1 includes production of the soluble form. J Biol Chem. 1994;269:17183–17191.[Abstract/Free Full Text]

9. Ohto H, Maeda H, Shibata Y, Chen R-F, Ozaki Y, Higashihara M, Takeuchi A, Tohyama H. A novel leukocyte differentiation antigen: two monoclonal antibodies TM2 and TM3 define a 120-kD molecule present on neutrophils, monocytes, platelets and activated lymphoblasts. Blood. 1985;66:873–881.[Abstract/Free Full Text]

10. Bogen S, Pak J, Garifallou M, Deng X, Muller WA. Monoclonal antibody to murine PECAM-1 (CD31) blocks acute inflammation in vivo. J Exp Med. 1994;179:1059–1064.[Abstract/Free Full Text]

11. Gumina RJ, Schultz JE, Yao Z, Kenny D, Warltier DC, Newman PJ, Gross GJ. Antibody to platelet/endothelial cell adhesion molecule-1 reduces myocardial infarct size in a rat model of ischemia-reperfusion injury. Circulation. 1996;94:3327–3333.[Abstract/Free Full Text]

12. Murohara T, Delyani JA, Albelda SM, Lefer AM. Blockade of platelet endothelial cell adhesion molecule-1 protects against myocardial ischemia and reperfusion injury in cats. J Immunol.. 1996;156:3550–3557.[Abstract]

13. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673–682.[Abstract/Free Full Text]

14. Ault KA. Flow cytometric measurement of platelet function and reticulated platelets. Ann N Y Acad Sci. 1993;677:293–308.[Medline] [Order article via Infotrieve]

15. Serebruany VL, Ordonez JV, Herzog WR, Rohde M, Mortensen SA, Folkers K, Gurbel PA. Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51/CD61) receptor expression. J Cardiovasc Pharmacol. 1997;29:16–22.[Medline] [Order article via Infotrieve]

16. O'Connor CM, Meese RB, McNulty S, Lucas KD, Carney RJ, LeBoeuf RM, Maddox W, Bethea CF, Shadoff N, Trahey TF, Heinsimer JA, Burks JM, O'Donnell G, Krucoff MW, Califf RM. A randomized factorial trial of reperfusion strategies and aspirin dosing in acute myocardial infarction: the DUCCS-II investigators. Am J Cardiol. 1996;77:791–797.[Medline] [Order article via Infotrieve]

17. Plow EF, Collen D. The presence and release of {alpha}2-antiplasmin from human platelets. Blood. 1981;58:1069–1074.[Abstract/Free Full Text]

18. Jang IK, Gold HK, Ziskind AA, Fallon JT, Holt RE, Leinbach RC, May JW, Collen D. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator: a possible explanation for resistance to coronary thrombolysis. Circulation. 1989;79:920–928.[Abstract/Free Full Text]

19. Eccleston D, Topol EJ. Inhibitors of platelet IIb/IIIa as augmentors of thrombolysis. Coron Artery Dis. 1995;6:947–955.[Medline] [Order article via Infotrieve]

20. Kleiman NS, Ohman EM, Califf RM, George BS, Kereiakes D, Aguirre FV, Weisman H, Schaible T, Topol EJ. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. J Am Coll Cardiol. 1993;22:381–389.[Abstract]

21. Gold HK, Garabedian HD, Dinsmore RE, Guerrero LJ, Cigarroa JE, Palacios IF, Leinbach RC. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators: observations in animals and humans. Circulation. 1997;95:1755–1759.[Abstract/Free Full Text]

22. Faraday N, Goldschmidt-Clermont P, Dise K, Bray PF. Quantitation of soluble fibrinogen binding to platelets by fluorescence-activated flow cytometry. J Lab Clin Med. 1994;123:728–740.[Medline] [Order article via Infotrieve]

23. Satoh K, Ozaki Y, Qi R, Yang L, Asazuma N, Yatomi Y, Kume S. Factors that affect the size of platelet aggregates in epinephrine induced activation: a study using the particle counting method based upon light scattering. Thromb Res. 1996;81:515–523.[Medline] [Order article via Infotrieve]

24. Hoyt CH, Lerea KM. Aggregation depending signaling in human platelets is sensitive to serine/threonine phospholipase inhibitors. Biochemistry. 1995;34:9565–9570.[Medline] [Order article via Infotrieve]

25. Jackson DE, Ward CM, Wang R, Newman PJ. The protein-tyrosine phosphatase SHP-2 binds platelet/endothelial cell adhesion molecule-1 (PECAM-1) and forms a distinct signaling complex during platelet aggregation: evidence for a mechanistic link between PECAM-1 and integrin-mediated cellular signaling. J Biol Chem. 1997;272:6986–6993.[Abstract/Free Full Text]

26. Rosenblum WI, Nelson GH, Wormley B, Werner P, Wang J, Shih CC. Role of platelet-endothelial cell adhesion molecule (PECAM) in platelet adhesion/aggregation over injured but not denuded endothelium in vivo and ex vivo. Stroke. 1996;27:709–711.[Abstract/Free Full Text]

27. Metzelaar MJ, Korteweg J, Sixma JJ, Nieuwenhuis HK. Comparison of platelet membrane markers for the detection of platelet activation in vitro and during platelet storage and cardiopulmonary bypass surgery. J Lab Clin Med. 1993;121:579–587.[Medline] [Order article via Infotrieve]

28. Galinanes M, Watson C, Trivedi U, Chambers DJ, Young CP, Venn GE. Differential patterns of neutrophil adhesion molecules during cardiopulmonary bypass in humans. Circulation. 1996;94(suppl II):II-364–II-369.

29. Adreotti F, Kluft C. Circadian variation of fibrinolytic activity in blood. Chronobiol Int. 1991;8:336–351.[Medline] [Order article via Infotrieve]

30. Modai I, Malmgren R, Asberg M, Beving H. Circadian rhythm of serotonin transport in human platelets. Psychopharmacology (Berl).. 1986;88:493–495.

31. Mores N, Martire M, Pistritto G, Volpe AR, Menini E, Folli G, Cardillo C. Platelet {alpha}2-adrenoceptors and diurnal changes of platelet aggregability in hypertensive patients. J Hypertens.. 1994;12:939–945.[Medline] [Order article via Infotrieve]

32. Krulder JW, de Boer A, van den Besselaar AM, Cohen AF, Schoemaker HC, Briet E, Meinders AE. Diurnal rhythm in anticoagulant effect of heparin during a low dose constant rate infusion: a study in healthy volunteers. Thromb Haemost. 1992;68:30–32.[Medline] [Order article via Infotrieve]

33. Wennmalm A, Benthin G, Granstrom EF, Persson L, Winell S. 2,3-Dinor metabolites of thromboxane A2 and prostacyclin in urine from healthy human subjects: diurnal variation and relation to 24h excretion. Clin Sci. 1992;83:461–465.[Medline] [Order article via Infotrieve]

34. Pepine CJ. Circadian variations in myocardial ischemia: implications for management. JAMA. 1991;265:386–390.[Abstract/Free Full Text]

35. Manfredini R, Gallerani M, Portaluppi F, Fersini C. Relationships of the circadian rhythms of thrombotic, ischemic, hemorrhagic, and arrhythmic events to blood pressure rhythms. Ann N Y Acad Sci.. 1996;783:141–158.[Medline] [Order article via Infotrieve]




This article has been cited by other articles:


Home page
Br J AnaesthHome page
C. Garcia, K. Julier, L. Bestmann, A. Zollinger, L. K. von Segesser, T. Pasch, D. R. Spahn, and M. Zaugg
Preconditioning with sevoflurane decreases PECAM-1 expression and improves one-year cardiovascular outcome in coronary artery bypass graft surgery
Br. J. Anaesth., February 1, 2005; 94(2): 159 - 165.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
V. L. Serebruany, A. H. Glassman, A. I. Malinin, C. B. Nemeroff, D. L. Musselman, L. T. van Zyl, M. S. Finkel, K. R. R. Krishnan, M. Gaffney, W. Harrison, et al.
Platelet/Endothelial Biomarkers in Depressed Patients Treated With the Selective Serotonin Reuptake Inhibitor Sertraline After Acute Coronary Events: The Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy
Circulation, August 26, 2003; 108(8): 939 - 944.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
V. L. Serebruany, S. R. Murugesan, A. Pothula, D. Atar, D. R. Lowry, C. M. O'Connor, and P. A. Gurbel
Increased soluble platelet / endothelial cellular adhesion molecule-1 and osteonectin levels in patients with severe congestive heart failure. Independence of disease etiology, and antecedent aspirin therapy
Eur J Heart Fail, August 31, 1999; 1(3): 243 - 249.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Serebruany, V. L.
Right arrow Articles by Gurbel, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Serebruany, V. L.
Right arrow Articles by Gurbel, P. A.
Related Collections
Right arrow Cardiovascular Pharmacology
Right arrow Anticoagulant mechanisms
Right arrow Acute myocardial infarction
Right arrow Platelets
Right arrow Endothelium/vascular type/nitric oxide